News | July 08, 2025
EMA and HMA to strengthen Anti-D Immunoglobulin supply chain
These medicines are essential in preventing RhD immunisation during pregnancy
These medicines are essential in preventing RhD immunisation during pregnancy
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The iStent platform uses tiny surgical implants to lower eye pressure by restoring the eye’s natural fluid drainage system in patients with glaucoma
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Subscribe To Our Newsletter & Stay Updated
